NEWS RELEASE

CareDx Launches HeartCare® for Heart Transplant Recipients

2018-04-10

HeartCare combines AlloMap and AlloSure-Heart for Comprehensive Rejection Surveillance

BRISBANE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the launch of HeartCare, a comprehensive rejection surveillance solution for heart transplant recipients.

HeartCare includes both AlloMap and AlloSure-Heart results for a holistic view into the health of a heart transplant patient. Clinical validity data for HeartCare will be presented at the International Society for Heart and Lung Transplantation (ISHLT) Annual 2018 Annual Meeting in Nice, France. CareDx will have a strong presence at ISHLT with several scientific presentations on AlloMap and AlloSure Heart scheduled.

“HeartCare gives physicians and patients access to otherwise invisible information, indicators of both their immune system activity and graft health," said Peter Maag, CEO of CareDx. "With AlloMap, clinicians have more than a decade of clinical experience and with AlloSure, we gain additional insights from donor-derived cell-free DNA testing. We are fulfilling our promise to make sequencing based information available to the transplant clinic, now also for heart transplant patients.”

The CareDx symposium “Comprehensive Surveillance of Heart Transplant Patients using HeartCare” will be held at ISHLT on Wednesday, April 11. Speakers include:

- Hannah Valantine, M.D., M.R.C.P., Senior Investigator, National Heart, Lung and Blood Institute, National Institutes of Health

- Kiran Khush, M.D., M.A.S., Associate Professor of Cardiovascular Medicine, Stanford University Medical Center
- Jon Kobashigawa, M.D., Thomas D. Gordon Professor of Medicine, and Director of the Heart Transplant Program, Cedars-Sinai Smidt Heart Institute
- Shelley Hall, M.D., Chief of Transplant Cardiology, Baylor University Medical Center

Four clinical abstracts featuring AlloMap or AlloSure-Heart will be presented by the study investigators:

Title: Donor-Derived Cell-Free DNA in D-OAR, a Real World, Clinical Use Heart Transplant Population

Presenter:Jon Kobashigawa, M.D., Cedars-Sinai Smidt Heart Institute

Title: Patterns of Gene Expression in High GEP Score Samples Correlated with Clinical Factors in the Outcomes AlloMap Registry

Presenter:Sean Pinney, M.D., Mount Sinai Health System

Title: Contribution of Individual Genes to Longitudinal Variation of Gene Expression Profile Scores

Presenter:Eugene DePasquale, M.D., UCLA Medical Center

Title: Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap® Registry

Presenter:Shelley Hall, M.D. Baylor University Medical Center

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure® for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: **www.CareDx.com**.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding our launch of HeartCare, as well as HeartCare's prospects. These forward-looking statements are based upon information that is currently available to us and our

current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by us with the SEC on March 22, 2018. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com

Source: CareDx, Inc.